ArticleOncotarget2020

Both BRCA1-wild type and -mutant triple-negative breast cancers show sensitivity to the NAE inhibitor MLN4924 which is enhanced upon MLN4924 and cisplatin combination treatment.

Shrilekha Misra et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.